Companies /Healthcare

Arcus Biosciences Inc

NYSE: RCUS Biotechnology
$15.62
▼ $0.16 (−1.01%) today
Markets closed · 4:45am ET

24/7 Wall St. View

RCUS at a Glance

Valuation
Market cap
$2.3B
Profitability
Revenue (TTM)
$100.0M
EPS (TTM)
$-3.64
Price
52-week range
$16 – $32
Street target
$40.92
Earnings
Q3 2026 EPS
$-1.00
vs. $-0.89 est.
−12.0%

Headquartered in Hayward, CA Fiscal year ends December NYSE: RCUS arcusbio.com

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company, founded in 2015, that develops small molecules, antibodies and combination therapies for cancer and immune diseases. It has no approved products. Its revenue comes from license and development services and other collaboration arrangements, mainly with Gilead (whose activities are winding down) and Taiho.

Oncology pipeline:
- Casdatifan, a HIF-2α inhibitor, is being developed as a backbone therapy across all lines of clear cell renal cell carcinoma.
- Casdatifan is in the Phase 3 PEAK-1 study (with cabozantinib, second line). The Phase 3 PEAK-20 study (with ipilimumab and nivolumab, first line) is set to start by year-end 2026, and PEAK-21 is planned.
- The ARC-20 platform study is testing casdatifan with zimberelimab, ivonescimab, tivozanib and others.
- Partner-sponsored studies with BMS (pumitamig) and Pfizer (tivunatamig) are also planned.
- Quemliclustat, a small-molecule CD73 inhibitor, is in the fully enrolled Phase 3 PRISM-1 trial in first-line metastatic pancreatic cancer.

Immunology pipeline:
- AB102, an oral MRGPRX2 antagonist, is in a first-in-human study.
- Preclinical programs include an oral TNFR1-selective TNF inhibitor, an oral CCR6 antagonist, a CD89 antibody, and oral STAT6 and CD40L inhibitors. Updated

Revenue by Segment · Q3 2026
  1. License and Development Service89%
  2. Other Collaboration11%

Latest Activity

RCUSArcus Biosciences
Q3 2026
EPS
-$1.00
est -$0.89-12.0%
Revenue
$9M
est $8M+8.8%

The Gilead collaboration is fading fast, with partnership reimbursements down to $12 million from $28 million a year ago, and the loss per share came in wider than expected because of it. A $694 million cash position funds operations into 2029, with PEAK-1 enrollment for casdatifan wrapping up in two to three months.

Quarterly EPS — reported vs estimate

RCUS Coverage

Frequently Asked Questions

What does Arcus Biosciences do?

Arcus Biosciences is a clinical-stage biopharmaceutical company, founded in 2015, that develops small molecules, antibodies and combination therapies for cancer and immune diseases. It has no approved products.

What is the RCUS stock price target?

The Wall Street consensus 12-month price target for RCUS is $40.92.